{"name":"Inhibrx","slug":"inhibrx","ticker":"INBX","exchange":"NASDAQ","domain":"inhibrx.com","description":"Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.","hq":"La Jolla, CA","founded":0,"employees":"109","ceo":"Mark Lappe","sector":"Oncology / Bispecific Antibodies","stockPrice":117.5,"stockChange":-0.45,"stockChangePercent":-0.38,"marketCap":"$1.7B","metrics":{"revenue":1300000,"revenueGrowth":-100,"grossMargin":0,"rdSpend":113028000,"netIncome":-140055000,"cash":124220000,"dividendYield":0,"peRatio":-42.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"INBX-101 patent cliff ($0.0B at risk)","drug":"INBX-101","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"INBX-103 patent cliff ($0.0B at risk)","drug":"INBX-103","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Inhibrx Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Inhibrx reported fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $44.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Inhibrx Announces Collaboration with Merck KGaA to Develop Bispecific Antibodies","summary":"Inhibrx announced a collaboration with Merck KGaA to develop bispecific antibodies for the treatment of various cancers.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Inhibrx Announces Positive Interim Results from Phase 1 Clinical Trial of INBX-101","summary":"Inhibrx announced positive interim results from a Phase 1 clinical trial of INBX-101, a bispecific antibody for the treatment of non-small cell lung cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPVUJmdGNOV2pJOUdrVnQ3aUtHWmZZckdmTzg0U2ZOYldSMTBwTEF0ek9CSENDU014Ym1rUmVUaEdIUHlPbDduMC1POUxHcHJscnM4ZUJlcTZuZFFfU0lpR0c4TVRwVjNKUGhSNVFtc0F6N2U4MzUxd080dWkwQ3gtV1hYRUhncjNxZnk5ZVhhRDJWU1ZQMDk2dTc3V3FVazdDWHFsbU9nLUVGZTdNakFQd2I3akxsOTNnbkh3bDJ3?oc=5","date":"2026-03-02","type":"pipeline","source":"PR Newswire","summary":"Inhibrx Announces Participation in Upcoming Scientific Conference - PR Newswire","headline":"Inhibrx Announces Participation in Upcoming Scientific Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNTDRKaXZZZEpFUkh2cW5hZ0lCbDhZS1RibDB5Y0JqcWlOTG9hVUxmVTIzblBKWUt2ak9UU1N1d2N0WmNvLWtZQkNobEdlSWd2cG9IaUgwUGxJYmZDTUswYnhOejZ0cGtPaDNCVmRvLUdBTHJKT01qT0VuRWtKS25rZVJIblMxbW16ZHR5TVhYS216MHBYSU83UUdjc0JMTUpLZm4zYlVRazhYY0gxQkE?oc=5","date":"2026-03-02","type":"trial","source":"Stock Titan","summary":"Ewing sarcoma study of ozekibart takes stage at rare cancer congress - Stock Titan","headline":"Ewing sarcoma study of ozekibart takes stage at rare cancer congress","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQYW9VUDgzaGVNamVKZUVJTG1Uc1VzUnQ1T1NxTTU3TWhuZGRTS1NDYWRWX3BHbW9wUV9qNm1KMTBMcXY2aHNjSlpNVEZHTGxtbWRTcG5zZjEtQXpUZ3RBU0dFcnVXdVFPYndFcUUtNlNTRnAxTVR0T3g0MFk2b050TTBXOWt2SXFGeU1OcVpEN19KRndLeHB3ekN6T0NaSmRkZHNOdmlHZVhNYngzWUtTcQ?oc=5","date":"2026-01-16","type":"pipeline","source":"Kalkine Media","summary":"Inhibrx Biosciences (NASDAQ:INBX) Nasdaq Futures Science-Driven Path - Kalkine Media","headline":"Inhibrx Biosciences (NASDAQ:INBX) Nasdaq Futures Science-Driven Path","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-18","type":"regulatory","source":"simplywall.st","summary":"Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates - simplywall.st","headline":"Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates","sentiment":"neutral"},{"date":"2025-12-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxONlp5WDJTWGFEaENTYmtkZTVVYWVOSmc2SVZZWVpObVMtMjdseWY3N1l2dHVDSkp3cnpsVEtNd09xWDMtQ3hpTVpiR0VEdVFfaDdRRkh6cTItalJBYURDLUhkRVVkTmRWZDhnQ29tR0Q2RThLQjBpdTdrYzU5M2tqZUZ2OEhLWlFiLThQQXF6dWpsSHU5M0dQei1WcGloMFpaTG40cHRhcUlGazhx?oc=5","date":"2025-11-14","type":"earnings","source":"PR Newswire","summary":"Inhibrx Reports Third Quarter 2025 Financial Results - PR Newswire","headline":"Inhibrx Reports Third Quarter 2025 Financial Results","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaUpyeWJyM0V4YWo0eHBXSW5nYk9TaEpSa0pRVzE5dTFNXzVkazMzNm1mU25QLVVVcnd6cjlCYmRoeXBORjk4MXlkNlc5SXdObFp2ZjJFTVVUeVJiRk9SckFlVExCM3B2cEFfcnlOQ1c1RUNBcTAyVkFRMXNiTlA3VlBfS3M0bE5mRVZTSWRRQ2NSaF85Q3B5RjlXZ1FKYUdtWDZCeEQ1NHlmRV9RM1QyU2lIRDJWbFh3?oc=5","date":"2025-10-27","type":"regulatory","source":"Seeking Alpha","summary":"Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself - Seeking Alpha","headline":"Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPcF96TFJTd2Nld0hpVmY1SklYN3Bpdkpxb0h4YXlENTl3VnhlemQyY214dlJ4anlqNkdsR09FU3kwT25QUi1DbG41V0Zaa29PWE8wa01FMFpDajc0bG5DTEdGa0VRYlNTSjRQRmRDZHlSbFlIeHBFdkVJWnA4U0o5cVd4Sk1ZekRBRnB4c2xiblh3UkduNGstLXJqeFZIaTMyeURyN3VnalVjdF9PQ0FrSU8talJpeU0?oc=5","date":"2025-10-24","type":"trial","source":"Seeking Alpha","summary":"Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing (NASDAQ:INBX) - Seeking Alpha","headline":"Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing (NASDAQ:INBX)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNLWx5c1ZibWhFVnd3WFdfeEo2cExHakdLX2NNTjdrU3NXNllqVk9wWGhmcU9HV3F2NjYtMmEyOHVBUFoyUlh0VU1ZUVpNcW1YRXRhWmJSOUJ1LVVRb2c4RlRIWVJZdE1SWTR0bjZnbWs3RnpoVWZxNG8yQnliYlh4TWV0dFY5VFRvVFgtMkVrMlJDU1RlQlRDQjVXU2pjRkJqS09KdHVjQWszN2Uwd1IxbEpZVzJiVk0?oc=5","date":"2025-10-23","type":"pipeline","source":"Stock Titan","summary":"Inhibrx Biosciences (Nasdaq: INBX) more than doubles median PFS in chondrosarcoma - Stock Titan","headline":"Inhibrx Biosciences (Nasdaq: INBX) more than doubles median PFS in chondrosarcoma","sentiment":"neutral"},{"date":"2025-10-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"INBX-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"INBX-103","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Bispecific Antibodies"],"financials":{"source":"sec_edgar+yahoo","revenue":1300000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1300000,"period":"2025-12-31"},{"value":200000,"period":"2024-12-31"},{"value":200000,"period":"2024-12-31"},{"value":1800000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":113028000,"rdSpendHistory":[{"period":"2025-12-31","value":113028000},{"period":"2024-12-31","value":203743000},{"period":"2023-12-31","value":191640000},{"period":"2022-12-31","value":101603000}],"sgaSpend":23118000,"operatingIncome":-135025000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-135025000},{"period":"2024-12-31","value":-331448000},{"period":"2023-12-31","value":-219221000},{"period":"2022-12-31","value":-115323000}],"netIncome":-140055000,"netIncomeHistory":[{"period":"2025-12-31","value":-140055000},{"period":"2024-12-31","value":1687572000},{"period":"2023-12-31","value":-241361000},{"period":"2022-12-31","value":-115325000}],"eps":-9.04,"epsHistory":[{"period":"2025-12-31","value":-9.04},{"period":"2024-12-31","value":112.62},{"period":"2023-12-31","value":-16.94811},{"period":"2022-12-31","value":-8.097998}],"cash":124220000,"cashHistory":[{"period":"2025-12-31","value":124220000},{"period":"2024-12-31","value":152596000},{"period":"2023-12-31","value":277924000}],"totalAssets":146478000,"totalLiabilities":138485000,"totalDebt":107012000,"equity":7993000,"operatingCashflow":-129794000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-129794000},{"period":"2024-12-31","value":-194409000},{"period":"2023-12-31","value":-193309000},{"period":"2022-12-31","value":-90811000}],"capex":-31000,"capexHistory":[{"period":"2025-12-31","value":-31000},{"period":"2024-12-31","value":-2597000},{"period":"2023-12-31","value":-4593000},{"period":"2022-12-31","value":-686000}],"freeCashflow":-129825000,"dividendsPaid":null,"buybacks":null,"employees":109,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5395000,"ebit":-29649000,"ebitda":-29085000,"period":"2025-12-31","revenue":0,"epsBasic":-2.11,"netIncome":-32834000,"rdExpense":25349000,"epsDiluted":-2.11,"grossProfit":null,"operatingIncome":-30923000},{"sga":5277000,"ebit":-32075000,"ebitda":-31492000,"period":"2025-09-30","revenue":0,"epsBasic":-2.28,"netIncome":-35256000,"rdExpense":28535000,"epsDiluted":-2.28,"grossProfit":null,"operatingIncome":-33812000},{"sga":6422000,"ebit":-25511000,"ebitda":-24850000,"period":"2025-06-30","revenue":1300000,"epsBasic":-1.85,"netIncome":-28654000,"rdExpense":22267000,"epsDiluted":-1.85,"grossProfit":null,"operatingIncome":-27389000},{"sga":6024000,"ebit":-40622000,"ebitda":-39947000,"period":"2025-03-31","revenue":0,"epsBasic":-2.8,"netIncome":-43311000,"rdExpense":36877000,"epsDiluted":-2.8,"grossProfit":null,"operatingIncome":-42901000},{"sga":16661000,"ebit":-47865000,"ebitda":-47176000,"period":"2024-12-31","revenue":100000,"epsBasic":-3.09,"netIncome":-47865000,"rdExpense":33367000,"epsDiluted":-3.09,"grossProfit":null,"operatingIncome":-49928000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":117.5,"previousClose":117.95,"fiftyTwoWeekHigh":155.29,"fiftyTwoWeekLow":10.97,"fiftyTwoWeekRange":"10.97 - 155.29","fiftyDayAverage":88.51,"twoHundredDayAverage":65.66,"beta":0,"enterpriseValue":1705691904,"forwardPE":-42.1,"priceToBook":214.42,"priceToSales":1320.27,"enterpriseToRevenue":1312.07,"enterpriseToEbitda":-12.87,"pegRatio":0,"ebitda":-132542000,"ebitdaMargin":0,"freeCashflow":-84456128,"operatingCashflow":-129794000,"totalDebt":107012000,"debtToEquity":1338.8,"currentRatio":3.93,"returnOnAssets":-51.6,"returnOnEquity":-197.8,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":2,"targetMeanPrice":265,"targetHighPrice":300,"targetLowPrice":230,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":23.3,"institutionHeldPercent":81.8,"sharesOutstanding":14607286,"floatShares":7805416,"sharesShort":2733548,"shortRatio":5.85,"shortPercentOfFloat":18.7,"epsTrailing":-9.03,"epsForward":-2.79,"revenuePerShare":0.08,"bookValue":0.55,"officers":[{"age":58,"name":"Mr. Mark Paul Lappe","title":"Founder, CEO & Chairman"},{"age":39,"name":"Mr. David J. Matly M.B.A.","title":"President"},{"age":45,"name":"Ms. Kelly Devine Deck B.S., CPA, M.S.","title":"Executive VP, CFO & Treasurer"},{"age":48,"name":"Ms. Bonne  Adams M.B.A.","title":"Vice President of Operations"},{"age":null,"name":"Ms. Kate  Burke CPA, M.B.A.","title":"Vice President of Accounting"},{"age":57,"name":"Dr. Ashraf  Amanullah Ph.D.","title":"Executive VP & Chief Technical Operations Officer"},{"age":null,"name":"Dr. Carlos  Bais Ph.D.","title":"EVP & Chief Scientific Officer"},{"age":null,"name":"Ms. Leah  Pollema J.D.","title":"VP, General Counsel & Corporate Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://inhibrx.com","phone":"858 795 4220"}}